Jianlin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianlin Wang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Bernard Mark Evers
University of Kentucky
24 shared publications - Bo Dong
Department of Pharmacology & Nutritional Sciences, University of Kentucky School of Medicine, Lexington, Kentucky
24 shared publications - Jiong Deng
Medical Research Center, Affiliated Hospital of Binzhou Medical University, Binzhou, China
24 shared publications - Tao Dai
Department of Pharmacology & Nutritional Sciences, University of Kentucky School of Medicine, Lexington, Kentucky
24 shared publications - Xiang Song
Department of Pharmacology & Nutritional Sciences, University of Kentucky School of Medicine, Lexington, Kentucky
24 shared publications - Xinzhao Wang
Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
24 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (31)
PLK1-mediated phosphorylation of PHGDH reprograms serine metabolism in advanced prostate cancer
Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to meet their increased biosynthetic and energetic demands. Although cells possess the capacity for de novo serine biosynthesis, most transformed cancer cells preferentially rely on exogenous serine uptake to sustain their growth, yet the regulatory mechanisms driving this metabolic dependency remain poorly understood. Here, we uncover a mechanism by which Polo-like kinase 1 (PLK1), frequently overexpressed in prostate cancer, orchestrates a metabolic shift in serine and sphingolipid metabolism through phosphorylation of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine synthesis pathway (SSP). Specifically, PLK1 directly phosphorylates PHGDH at S512, S513, and S517, leading to a marked reduction in its protein level and enzymatic activity. This downregulation of de novo serine biosynthesis forces cancer cells to increase their reliance on exogenous serine uptake via the ASCT2 transporter, which in turn fuels the biosynthesis of lipids, including sphingolipids essential for tumor growth and survival. Our findings suggest that targeting the SSP, serine uptake, or downstream lipid biosynthesis pathways may represent promising therapeutic strategies in advanced cancers characterized by PLK1 dysregulation.
- 27 July 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (31)
Open AccessPLK1-mediated phosphorylation of PHGDH reprograms serine metabolism in advanced prostate cancer
Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to meet their increased biosynthetic and energetic demands. Although cells possess the capacity for de novo serine biosynthesis, most transformed cancer cells preferentially rely on exogenous serine uptake to sustain their growth, yet the regulatory mechanisms driving this metabolic dependency remain poorly understood. Here, we uncover a mechanism by which Polo-like kinase 1 (PLK1), frequently overexpressed in prostate cancer, orchestrates a metabolic shift in serine and sphingolipid metabolism through phosphorylation of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine synthesis pathway (SSP). Specifically, PLK1 directly phosphorylates PHGDH at S512, S513, and S517, leading to a marked reduction in its protein level and enzymatic activity. This downregulation of de novo serine biosynthesis forces cancer cells to increase their reliance on exogenous serine uptake via the ASCT2 transporter, which in turn fuels the biosynthesis of lipids, including sphingolipids essential for tumor growth and survival. Our findings suggest that targeting the SSP, serine uptake, or downstream lipid biosynthesis pathways may represent promising therapeutic strategies in advanced cancers characterized by PLK1 dysregulation.
- 18 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (878) , eadi5174
The kinase PLK1 promotes Hedgehog signaling–dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer
Enzalutamide, a second-generation androgen receptor inhibitor (also known as an antiandrogen), is used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Tumors often acquire resistance to enzalutamide. Tumor progression and enzalutamide resistance are associated with decreased abundance of the tumor suppressor PDCD4. In normal dividing cells, PDCD4 abundance is low when that of the kinase PLK1 is high. In this study, we found that PLK1 acted on PDCD4 to promote enzalutamide resistance in CRPC cells in culture and in mice via a mechanism that revealed an effective combination therapy. PLK1 phosphorylated PDCD4 at Ser 239 , leading to its degradation and consequently inducing the transcriptional activation of Hedgehog (Hh) signaling by c-MYC. Hh signaling supports tumor cell proliferation and stemness by inducing the enzyme UDP-glucuronosyltransferase 2B15 (UGT2B15), which promotes the metabolic clearance of drugs and steroid hormones. Thus, this pathway may circumvent androgen receptor dependence, thereby reducing cellular sensitivity to enzalutamide. Knocking down UGT2B15 enhanced enzalutamide-induced cell apoptosis and growth arrest in a PDCD4-dependent manner. Combining enzalutamide with the clinically approved Hh pathway inhibitor vismodegib inhibited cell growth and promoted apoptosis in enzalutamide-resistant cell cultures and xenografts in vivo. Our findings reveal a mechanism of PLK1-mediated enzalutamide resistance and suggest a potential therapeutic strategy to overcome this resistance in prostate cancer.
- 18 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (878) , eadi5174
The kinase PLK1 promotes Hedgehog signaling–dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer
Enzalutamide, a second-generation androgen receptor inhibitor (also known as an antiandrogen), is used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Tumors often acquire resistance to enzalutamide. Tumor progression and enzalutamide resistance are associated with decreased abundance of the tumor suppressor PDCD4. In normal dividing cells, PDCD4 abundance is low when that of the kinase PLK1 is high. In this study, we found that PLK1 acted on PDCD4 to promote enzalutamide resistance in CRPC cells in culture and in mice via a mechanism that revealed an effective combination therapy. PLK1 phosphorylated PDCD4 at Ser 239 , leading to its degradation and consequently inducing the transcriptional activation of Hedgehog (Hh) signaling by c-MYC. Hh signaling supports tumor cell proliferation and stemness by inducing the enzyme UDP-glucuronosyltransferase 2B15 (UGT2B15), which promotes the metabolic clearance of drugs and steroid hormones. Thus, this pathway may circumvent androgen receptor dependence, thereby reducing cellular sensitivity to enzalutamide. Knocking down UGT2B15 enhanced enzalutamide-induced cell apoptosis and growth arrest in a PDCD4-dependent manner. Combining enzalutamide with the clinically approved Hh pathway inhibitor vismodegib inhibited cell growth and promoted apoptosis in enzalutamide-resistant cell cultures and xenografts in vivo. Our findings reveal a mechanism of PLK1-mediated enzalutamide resistance and suggest a potential therapeutic strategy to overcome this resistance in prostate cancer.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental Table S3. Tumor samples used for analysis
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental Table S3. Tumor samples used for analysis
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The used antibodies including company, catalog number and dilution.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The used antibodies including company, catalog number and dilution.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 regulates LSD1 at protein levels.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 regulates LSD1 at protein levels.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The sequence of primers for RT-qPCR and ChIP-qPCR.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The sequence of primers for RT-qPCR and ChIP-qPCR.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The expression of FBXO24 is inversely associated with the expression of LSD1.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The expression of FBXO24 is inversely associated with the expression of LSD1.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 blocks tumor migration and invasion.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 blocks tumor migration and invasion.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.